Press-release for stocks in the health technology sector

Prices are updated after-hours

sector : Health technology crawled date : 2021 - 10 - 20

save search

SeaSpine to Report Third Quarter 2021 Financial Results on October 28, 2021
Published: 2021-10-20 (Crawled : 23:00) - biospace.com/
SPNE | $9.54 8.29% -1.99%

Health Technology

| -36.9% | O: 0.4% H: 0.46% C: -0.4%
spine financial results results

Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021
Published: 2021-10-20 (Crawled : 23:00) - prnewswire.com
ILMN | $117.43 0.63% 0.63% 1.4M

Health Technology

| -71.39% | O: 0.66% H: 0.43% C: -1.1%

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
Published: 2021-10-20 (Crawled : 23:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -11.5% | O: 0.32% H: 0.05% C: -0.55%
covid fda authorized vaccine merge covid-19

Neurona Therapeutics Appoints Brad Margus to its Board of Directors
Published: 2021-10-20 (Crawled : 23:00) - biospace.com/
ARVN | $34.78 1.43% 1.41% 940K

Health Technology

| -59.6% | O: 0.39% H: 8.3% C: 2.39%
therapeutics

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
Published: 2021-10-20 (Crawled : 23:00) - biospace.com/
MOR | News | $17.96 -0.5% -0.5% 180K

Health Technology

| 58.47% | O: 0.0% H: 0.88% C: -0.79%
IMAB | $1.81 0.56% 0.55% 340K

Health Technology

| -97.26% | O: 0.2% H: 3.08% C: 0.91%
phase 2 nephropathy

CytoSorbents Comments on REMOVE Study Presentation
Published: 2021-10-20 (Crawled : 23:00) - cytosorbents.com
CTSO | $0.8026 0.2% 0.2% 46K

Health Technology

| -86.69% | O: 0.67% H: 3.64% C: -0.17%
presentation

Worldwide Ophthalmic Drugs Industry to 2029 - by Prescription Type, Therapeutic Type and Geography
Published: 2021-10-20 (Crawled : 22:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| 13.84% | O: 3.45% H: 0.0% C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -40.61% | O: 0.6% H: 0.08% C: -0.45%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| 10.19% | O: 0.18% H: 0.27% C: 0.06%
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology

| -11.5% | O: 0.32% H: 0.05% C: -0.55%
drug

Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults
Published: 2021-10-20 (Crawled : 22:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -39.61% | O: 0.07% H: 2.35% C: 1.61%
vaccine pneumococcal

Sorrento Announces That COVISTIX™ (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device
Published: 2021-10-20 (Crawled : 22:00) - biospace.com/
SRNE | $0.024 -8.85% 57K

Health Technology

| -99.7% | O: -0.59% H: 0.75% C: -2.99%
covid ce mark test device

Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
Published: 2021-10-20 (Crawled : 22:00) - biospace.com/
EVOK | $0.493 2.97% 2.88% 1.9K

Health Technology

| -63.57% | O: -2.33% H: 3.97% C: 1.59%
positive research pharma

Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
Published: 2021-10-20 (Crawled : 22:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| -68.99% | O: 0.12% H: 1.37% C: -0.3%
covid fda vaccine covid-19

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology
Published: 2021-10-20 (Crawled : 22:00) - biospace.com/
GLTO | $0.72 4.71% 77K

Health Technology

| -79.01% | O: 0.0% H: 3.5% C: 3.5%
phase 2 fibrosis trial phase 2b

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Published: 2021-10-20 (Crawled : 22:00) - globenewswire.com
IVA | $3.35 -2.9% -2.99% 8.5K

Health Technology

| -77.0% | O: 3.57% H: 0.0% C: -1.66%
results nash trial

FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Published: 2021-10-20 (Crawled : 22:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.22% | O: -0.08% H: 0.41% C: 0.41%
REGN | $896.27 0.26% 0.25% 500K

Health Technology

| 60.15% | O: 0.31% H: 1.14% C: 0.87%
fda children approval dupixent

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
RDUS | $18.41 -0.61% -0.61% 220K

Health Technology

| 21.02% | O: 36.48% H: 9.0% C: -14.74%
positive results cancer topline elacestrant phase 3 breast cancer trial elascestrant

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
FUSN | $21.26 0.05% 0.05% 440K

Health Technology

| 188.2% | O: -0.14% H: 3.22% C: 2.99%
presentation preclinical therapy pre-clinical

vTv Therapeutics Announces Deepa Prasad as New President and CEO
Published: 2021-10-20 (Crawled : 21:00) - biospace.com/
DSGN | $3.695 -1.2% -1.22% 390K

Professional, Scientific, and T...

| -73.47% | O: 1.15% H: 5.26% C: 3.13%
VTVT | $24.74 -0.21% 2K

Health Technology

| 1582.99% | O: 0.0% H: 0.67% C: 0.0%
ceo leo therapeutics

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Published: 2021-10-20 (Crawled : 21:00) - crinetics.com
CRNX | $42.98 -0.07% -0.07% 620K

Health Technology

| 119.65% | O: 7.96% H: 9.36% C: 5.58%
offering publication

ADMA Biologics Announces Proposed Public Offering of Common Stock
Published: 2021-10-20 (Crawled : 21:00) - admabiologics.com
ADMA 4 | $6.27 1.13% 1.12% 3.4M

Health Technology